CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate
Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
15-Feb-2021 -
CureVac N.V. announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, the company’s mRNA-based COVID-19 vaccine candidate, currently in late-stage clinical testing. The process was initiated when the first data package consisting of CVnCoV pre-clinical ...
coronaviruses
Covid-19
CureVac
+3